India · Delayed Price · Currency is INR Kimia Biosciences Company Description
Kimia Biosciences Limited engages in the manufacturing and sale of pharmaceutical products in India and internationally.
The company offers active pharmaceutical ingredients (APIs) in various therapeutic categories, including gastrointestinal agent, anti-coagulant, anti-hypertensive, vitamin B1, anti-histamine, anti-convulsant, central stimulant, anti-diabetic, anti-fungal, overactive bladder, anti-inflammatory, prokinetic agent, and hepatoprotective agent, as well as lipid lowering agent, thiamine supplement, anti-acne, NSAID, cholerectic agent, anti-bacterial, anti – ulcer/GERD, and anti-depressant.
It also develops APIs for anti-psychotic, liver/metabolic disease agent, COPD/respiratory agent, COPD/respiratory agent, neuropathic pain agent, anti-migraine, and immunosuppressant.
In addition, the company offers and develops KSMs, intermediates, and reagents. Further, it provides contract research and manufacturing and development services.
The company also exports its products. Kimia Biosciences Limited was formerly known as Laurel Organics Ltd and changed its name to Kimia Biosciences Limited January 2019.
The company was incorporated in 1993 and is based in New Delhi, India.
| Country | India |
| Founded | 1993 |
| Industry | Medicinal Chemicals and Botanical Products |
| Employees | 205 |
| CEO | Sameer Goel |
Contact Details
Address: 974, Aggarwal Millennium Tower II New Delhi, Haryana 110034 India | |
| Phone | 91 11 4706 3600 |
| Website | kimiabiosciences.com |
Stock Details
| Ticker Symbol | 530313 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Sameer Goel | Chief Executive Officer |
| Mani Jain | Chief Financial Officer |